Zobrazeno 1 - 10
of 733
pro vyhledávání: '"Patrick Schöffski"'
Autor:
Tom Vandaele, Jan Van Slambrouck, Patrick Schöffski, Herlinde Dumez, Birgit Weynand, Raf Sciot, Annalisa Barbarossa, An-Lies Provoost, Kristof Van de Voorde, Yves Debaveye, Sofian Bouneb, Philippe Nafteux, Laurens J. Ceulemans
Publikováno v:
World Journal of Surgical Oncology, Vol 22, Iss 1, Pp 1-12 (2024)
Abstract Background Pleural neoplasms are rare and can be subdivided into pleural metastasis and primary pleural neoplasms. Non-mesothelioma primary pleural neoplasms are a diverse group of extremely rare pathologies. Case presentation In this case s
Externí odkaz:
https://doaj.org/article/3b9699ca8efa44beb4a7a5afbe584a46
Autor:
Sophie Leboulleux, Ellen Kapiteijn, Saskia Litière, Patrick Schöffski, Yann Godbert, Patrice Rodien, Barbara Jarzab, Domenico Salvatore, Sylvie Zanetta, Jaume Capdevila, Lars Bastholt, Christelle De La Fouchardiere, Yassine Lalami, Stéphane Bardet, Frank Cornélis, Marek Dedecjus, Thera Links, Ward Sents, Martin Schlumberger, D. Laura Locati, Katie Newbold
Publikováno v:
Frontiers in Endocrinology, Vol 15 (2024)
BackgroundNintedanib is a triple-angiokinase inhibitor with potential activity in patients with advanced thyroid cancers, as radioiodine refractory differentiated thyroid cancer (RAIR DTC) and medullary thyroid cancer (MTC).DesignEORTC-1209 (NCT01788
Externí odkaz:
https://doaj.org/article/6cb94876a3044358996b174c5e0cfcd4
Autor:
Rafael Zago Baltazar, Sofie Claerhout, Sara Vander Borght, Lien Spans, Raphael Sciot, Patrick Schöffski, Daphne Hompes, Friedl Sinnaeve, Hazem Wafa, Marleen Renard, Mari FCM van den Hout, Astrid Vernemmen, Louis Libbrecht, An‐Katrien De Roo, Filomena Mazzeo, Cédric van Marcke, Karen Deraedt, Claire Bourgain, Isabelle Vanden Bempt
Publikováno v:
The Journal of Pathology: Clinical Research, Vol 10, Iss 3, Pp n/a-n/a (2024)
Abstract The identification of gene fusions has become an integral part of soft tissue and bone tumour diagnosis. We investigated the added value of targeted RNA‐based sequencing (targeted RNA‐seq, Archer FusionPlex) to our current molecular diag
Externí odkaz:
https://doaj.org/article/a4e531c2073947398417e6e0aa6c457f
Autor:
Patrick Schöffski, Suzanne George, Michael C. Heinrich, John R. Zalcberg, Sebastian Bauer, Hans Gelderblom, César Serrano, Robin L. Jones, Steven Attia, Gina D’Amato, Ping Chi, Peter Reichardt, Claus Becker, Kelvin Shi, Julie Meade, Rodrigo Ruiz-Soto, Jean-Yves Blay, Margaret von Mehren
Publikováno v:
BMC Cancer, Vol 22, Iss 1, Pp 1-10 (2022)
Abstract Background Ripretinib is a novel switch-control kinase inhibitor that inhibits KIT and PDGFRA signaling. In the INVICTUS phase 3 trial, ripretinib increased median progression-free survival and prolonged overall survival vs. placebo in ≥ f
Externí odkaz:
https://doaj.org/article/9bb5658e944d433ba93df74a037e4505
Autor:
Chia-Chi Lin, Elena Garralda, Patrick Schöffski, David S. Hong, Lillian L. Siu, Miguel Martin, Michela Maur, Rina Hui, Ross A Soo, Joanne Chiu, Tian Zhang, Brigette Ma, Chrisann Kyi, Daniel SW Tan, Philippe A. Cassier, John Sarantopoulos, Andrew Weickhardt, Richard D. Carvajal, Jennifer Spratlin, Taito Esaki, Fréderic Rolland, Wallace Akerley, Barbara Deschler-Baier, Lawrence Rispoli, Tanay S. Samant, Niladri Roy Chowdhury, Daniel Gusenleitner, Eunice L. Kwak, Vasileios Askoxylakis, Filippo De Braud
Publikováno v:
OncoImmunology, Vol 13, Iss 1 (2024)
ABSTRACTIeramilimab, a humanized anti-LAG-3 monoclonal antibody, was well tolerated in combination with the anti-PD-1 antibody spartalizumab in a phase 1 study. This phase 2 study aimed to further investigate the efficacy and safety of combination tr
Externí odkaz:
https://doaj.org/article/fba32163599d40e7abcb0008f2589a1a
Autor:
Maria A. Pantaleo, Michael C. Heinrich, Antoine Italiano, Claudia Valverde, Patrick Schöffski, Giovanni Grignani, Anna K. L. Reyners, Sebastian Bauer, Peter Reichardt, Daniel Stark, Ghimja Berhanu, Ulrike Brandt, Tommaso Stefanelli, Hans Gelderblom
Publikováno v:
BMC Cancer, Vol 22, Iss 1, Pp 1-8 (2022)
Abstract Background Acquired resistance to approved tyrosine kinase inhibitors limits their clinical use in patients with gastrointestinal stromal tumor (GIST). This study investigated the safety, tolerability and efficacy of alpelisib, a phosphatidy
Externí odkaz:
https://doaj.org/article/2f1e77cece464909a2d9a3ecf8c75f78
Autor:
Szymon Macioszek, Danuta Dudzik, Rafał Bartoszewski, Tomasz Stokowy, Diether Lambrechts, Bram Boeckx, Agnieszka Wozniak, Patrick Schöffski, Michał J. Markuszewski
Publikováno v:
Translational Oncology, Vol 30, Iss , Pp 101632- (2023)
Background: Although imatinib is a well-established first-line drug for treating a vast majority of gastrointestinal stromal tumours (GIST), GISTs acquire secondary resistance during therapy. Multi-omics approaches provide an integrated perspective t
Externí odkaz:
https://doaj.org/article/45e412c3a749489d854a7e0c278adf19
Autor:
Lisa Kinget, Oliver Bechter, Kevin Punie, Philip R. Debruyne, Hilde Brems, Paul Clement, Eduard Roussel, Yannick Van Herck, Maarten Albersen, Marcella Baldewijns, Patrick Schöffski, Benoit Beuselinck
Publikováno v:
Current Oncology, Vol 28, Iss 5, Pp 3227-3239 (2021)
In recent years, immune checkpoint inhibitors (ICPI) have become widely used for multiple solid malignancies. Reliable predictive biomarkers for selection of patients who would benefit most are lacking. Several tumor types with somatic or germline al
Externí odkaz:
https://doaj.org/article/7a39b9d2c6fd430fa1ce2c4042e5f079
Autor:
Anne-Sophie Van de Velde, Nina De Moor, Thomas Meyskens, Isabelle Vanden Bempt, Melissa Christiaens, Patrick Schöffski
Publikováno v:
Current Problems in Cancer: Case Reports, Vol 5, Iss , Pp 100134- (2022)
Introduction: Hepatoid adenocarcinoma (HAC) is a rare neoplasm with a poor prognosis that shows morphological and biochemical similarities to hepatocellular carcinoma. It can occur at any anatomical site, predominantly in the stomach. So far, HAC of
Externí odkaz:
https://doaj.org/article/a58ebcc0589b44cd9c0a98f01559090b
Autor:
Tian Zhang, Filippo de Braud, Taito Esaki, Wallace Akerley, Chrisann Kyi, Richard D Carvajal, Daniel Gusenleitner, Patrick Schöffski, Miguel Martin, David S Hong, Amy Prawira, Jürgen Krauß, Nidhi Patel, Rina Hui, Andrew Weickhardt, Niladri Roy Chowdhury, Daniel S W Tan, María Ochoa-de-Olza, John Sarantopoulos, Ross A Soo, Michela Maur, Barbara Deschler-Baier, Allen Lau, Tanay S Samant, Tyler Longmire, Catherine A Sabatos-Peyton, Radha Ramesh, Tiancen Hu, Ana Carion, Padmaja Yerramilli-Rao, Vasileios Askoxylakis, Eunice L Kwak
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 10, Iss 2 (2022)
Externí odkaz:
https://doaj.org/article/c14ae2c468844f0d8af45992b1b6b8f2